Abstract
Purpose of review Minimally invasive options to treat low-risk prostate cancer are more desirable than radical therapy. Technological improvements in cryotherapy have increased its use, and long-term data on its efficacy are emerging. In this review, we discuss contemporary data on cryotherapy with specific focus on studies using the newest technology. Recent findings With respect to biochemical recurrence rates, cryotherapy appears to be as effective for low-risk prostate cancer as other treatment modalities. The definition of recurrence remains problematic, though contemporary studies are more consistently using both the American Society for Therapeutic Radiation Oncology and Phoenix criteria. Erectile dysfunction rates are universally high after whole-gland cryoablation, but incontinence and urethrorectal fistula rates appear to be low with third-generation cryo systems. Focal cryotherapy has encouraging short-term efficacy in terms of biochemical disease-free survival rate for unifocal disease, and rates of erectile dysfunction are dramatically lower than those seen with whole-gland cryoablation. Summary Cryosurgery has a promising role in primary and salvage treatment of select prostate cancer patients. Focal cryotherapy for unilateral disease offers the added benefit of minimal adverse effects. Long-term data are emerging to support cryosurgery, and large multicenter databases have been developed to answer questions regarding optimal treatment outcomes and patterns.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 177-181 |
| Number of pages | 5 |
| Journal | Current Opinion in Urology |
| Volume | 19 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 2009 |
| Externally published | Yes |
Fingerprint
Keywords
- Cryosurgery
- Focal therapy
- Prostate cancer
ASJC Scopus subject areas
- Urology
Cite this
Prostate cryotherapy : Current status. / Ritch, Chad; Katz, Aaron E.
In: Current Opinion in Urology, Vol. 19, No. 2, 03.2009, p. 177-181.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prostate cryotherapy
T2 - Current status
AU - Ritch, Chad
AU - Katz, Aaron E.
PY - 2009/3
Y1 - 2009/3
N2 - Purpose of review Minimally invasive options to treat low-risk prostate cancer are more desirable than radical therapy. Technological improvements in cryotherapy have increased its use, and long-term data on its efficacy are emerging. In this review, we discuss contemporary data on cryotherapy with specific focus on studies using the newest technology. Recent findings With respect to biochemical recurrence rates, cryotherapy appears to be as effective for low-risk prostate cancer as other treatment modalities. The definition of recurrence remains problematic, though contemporary studies are more consistently using both the American Society for Therapeutic Radiation Oncology and Phoenix criteria. Erectile dysfunction rates are universally high after whole-gland cryoablation, but incontinence and urethrorectal fistula rates appear to be low with third-generation cryo systems. Focal cryotherapy has encouraging short-term efficacy in terms of biochemical disease-free survival rate for unifocal disease, and rates of erectile dysfunction are dramatically lower than those seen with whole-gland cryoablation. Summary Cryosurgery has a promising role in primary and salvage treatment of select prostate cancer patients. Focal cryotherapy for unilateral disease offers the added benefit of minimal adverse effects. Long-term data are emerging to support cryosurgery, and large multicenter databases have been developed to answer questions regarding optimal treatment outcomes and patterns.
AB - Purpose of review Minimally invasive options to treat low-risk prostate cancer are more desirable than radical therapy. Technological improvements in cryotherapy have increased its use, and long-term data on its efficacy are emerging. In this review, we discuss contemporary data on cryotherapy with specific focus on studies using the newest technology. Recent findings With respect to biochemical recurrence rates, cryotherapy appears to be as effective for low-risk prostate cancer as other treatment modalities. The definition of recurrence remains problematic, though contemporary studies are more consistently using both the American Society for Therapeutic Radiation Oncology and Phoenix criteria. Erectile dysfunction rates are universally high after whole-gland cryoablation, but incontinence and urethrorectal fistula rates appear to be low with third-generation cryo systems. Focal cryotherapy has encouraging short-term efficacy in terms of biochemical disease-free survival rate for unifocal disease, and rates of erectile dysfunction are dramatically lower than those seen with whole-gland cryoablation. Summary Cryosurgery has a promising role in primary and salvage treatment of select prostate cancer patients. Focal cryotherapy for unilateral disease offers the added benefit of minimal adverse effects. Long-term data are emerging to support cryosurgery, and large multicenter databases have been developed to answer questions regarding optimal treatment outcomes and patterns.
KW - Cryosurgery
KW - Focal therapy
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=61349130701&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=61349130701&partnerID=8YFLogxK
U2 - 10.1097/MOU.0b013e32831e16ce
DO - 10.1097/MOU.0b013e32831e16ce
M3 - Article
C2 - 19195130
AN - SCOPUS:61349130701
VL - 19
SP - 177
EP - 181
JO - Current Opinion in Urology
JF - Current Opinion in Urology
SN - 0963-0643
IS - 2
ER -